Impaired glucose homeostasis in renal transplant recipients receiving basiliximab

Nephrology Dialysis Transplantation

Volumn 25, Issue 4, 2010, Pages 1289-1293

  Aasebø, Willy ^a   Midtvedt, Karsten ^a   Valderhaug, Tone Gretland ^a   Leivestad, Torbjørn ^a   Hartmann, Anders ^a,b   Reisæter, Anna Varberg ^a   Jenssen, Trond ^a,c   Holdaas, Hallvard ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Diabetes mellitus; Immunosuppression; Kidney transplantation; Pathogenesis

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; GLUCOSE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GRAFT RECIPIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES AFTER TRANSPLANTATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; FEMALE; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; HOMEOSTASIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77950209775     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp617     Document Type: Article

References (21)

1. Kasiske B, Snyder D, Gilbertone D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185
2. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes on survival and major cardiac events. Kidney int 2006; 69: 588-595
3. Obayashi PAC. Posttransplant diabetes mellitus: cause, impact, and treatment options. Nutr Clin Pract 2004; 19: 165-171
4. Cosio FG, Pesavento TE, Osei K, et al. Posttransplant diabetes melli-tus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59: 732-737
5. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-983
6. Hjelmesæth J, Sagedal S, Hartmann A, et al. Asymptomatic CMV infection is associated with increased risk of new onset diabetes mel-litus and impaired insulin release after renal transplantation. Diabe-tologia 2004; 47: 1550-1556
7. Valderhaug TG, Hjelmesaeth J, Rollag H, et al. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007; 84: 1125-1130
8. Rodrigo E, Fernadez-Fresnedo G, Valero R, et al. New-onset diabetes mellitus after kidney transplantation: risk factors. J Am Soc Nephrol 2006; 17: 291
9. Hjelmesæth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001; 16: 829-831
10. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4: 583-595
11. Hjelmesæth J, Hagen LT, Åsberg A, et al. The impact of short-term cyclosporine. A treatment on insulin secretion and insulin sensitivity in man. Nephrol Dial Transplant 2007; 22: 1743-1749
12. Johnston L, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418
13. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transpl 2008; 8: 2086-2096
14. Morran MP, Omenn GS, Pietropaolo M. Immunology and genetics of type 1 diabetes. Mt Sinai J Med 2008; 75: 314-327
15. Brusko T, Bluestone J. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur J Immunol 2008; 38: 931-934
16. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201: 723-735
17. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World health organization, 1999
18. Porrini E, Delgado P, Alvarez A, et al. The combined effect of pre-transplant triglyceride levels and type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant 2008; 23: 1436-1441
19. Roland M, Gatault P, Doute C, et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008; 6: 523-530
20. Wang Z, Shi BY, Qian YY, et al. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. Clin Exp immunol 2009; 155: 496-503
21. Gutierrez-Ramos JC, Andreu JL, Revilla Y, et al. Recovery from au-toimmunity of MRL/lpr mice after infection with an interleukin-2/vaccine recombinant virus. Nature 1990; 346: 271-274